This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chatterjee, K. Articles by Norman, A. Search for Related Content PubMed PubMed Citation Articles by Chatterjee, K. Articles by Norman, A.

Circulation, Vol 54, 879-883, Copyright © 1976 by American Heart Association

ARTICLES

Oral hydralazine therapy for chronic refractory heart failure

K Chatterjee, WW Parmley, B Massie, B Greenberg, J Werner, S Klausner and A Norman

The hemodynamic effects of oral hydralazine were investigated in ten patients (nine in NYHA Class IV and one in Class III) with chronic refractory heart failure. With hemodynamic monitoring, adequate oral doses of hydralazine (50 or 75 mg) were determined and then administered every six hours. Hemodynamics were determined at 2-3, 6-8 and 24 hours on hydralazine therapy. Arterial pressure decreased slightly (5%) and systemic vascular resistance decreased significantly (42%). Cardiac and stroke volume index increased by 70 and 66%, respectively, without any significant change in heart rate, pulmonary capillary wedge or right atrial pressure. Hemodynamic improvement was associated with clinical improvement without a major complication. During the follow-up period of 3-7 months, seven of nine patients were in NYHA Class II and one in Class III. One other patient died suddenly six weeks after discharge. These findings suggest that hydralazine in an effective oral vasodilator for the treatment of refractory heart failure.

This article has been cited by other articles:

				M. S. Nieminen Pharmacological options for acute heart failure syndromes: current treatments and unmet needs Eur. Heart J. Suppl., April 1, 2005; 7(suppl_B): B20 - B24. [Abstract] [Full Text] [PDF]

				K. Chatterjee Heart Failure Therapy in Evolution Circulation, December 1, 1996; 94(11): 2689 - 2693. [Full Text]

				A. J. Manolis, C. Olympios, M. Sifaki, S. Handanis, M. Bresnahan, I. Gavras, and H. Gavras Suppressing Sympathetic Activation in Congestive Heart Failure : A New Therapeutic Strategy Hypertension, November 1, 1995; 26(5): 719 - 724. [Abstract] [Full Text]

				D. L. Groden Vasodilator Therapy for Congestive Heart Failure: Lessons From Mortality Trials Arch Intern Med, February 22, 1993; 153(4): 445 - 454. [Abstract] [PDF]

				M. PACKER Vasodilator Therapy for Primary Pulmonary Hypertension: Limitations and Hazards Ann Intern Med, August 1, 1985; 103(2): 258 - 270. [Abstract] [PDF]

				A. A. Losardo, N. A. Klein, N. Beer, J. A. Strom, J. P. Wexler, E. H. Sonnenblick, and W. H. Frishman Beneficial Effects of Sublingual Nifedipine in Patients with Ischemic Heart Disease and Depressed Left Ventricular Function Angiology, December 1, 1982; 33(12): 811 - 817. [Abstract] [PDF]

				B. H. GREENBERG, R. SCHUTZ, G. L. GRUNKEMEIER, and H. GRISWOLD Acute Effects of Alcohol in Patients with Congestive Heart Failure Ann Intern Med, August 1, 1982; 97(2): 171 - 175. [Abstract] [PDF]

				R. C. Little and W. C. Little Cardiac Preload, Afterload, and Heart Failure Arch Intern Med, April 1, 1982; 142(4): 819 - 822. [Abstract] [PDF]

				R. D. MAGORIEN, D. W. TRIFFON, C. E. DESCH, W. H. BAY, D. V. UNVERFERTH, and C. V. LEIER Prazosin and Hydralazine in Congestive Heart Failure: Regional Hemodynamic Effects in Relation to Dose Ann Intern Med, July 1, 1981; 95(1): 5 - 13. [Abstract] [PDF]

				R. M. Gunnar The Role of Vasodilating Agents in the Treatment of Chronic Heart Failure Angiology, August 1, 1980; 31(8): 526 - 532. [PDF]

				K. CHATTERJEE, T. A. PORTS, B. H. BRUNDAGE, B. MASSIE, A. N. HOLLY, and W. W. PARMLEY Oral Hydralazine in Chronic Heart Failure: Sustained Beneficial Hemodynamic Effects Ann Intern Med, May 1, 1980; 92(5): 600 - 604. [Abstract] [PDF]

				S. B. ARNOLD, R. L. WILLIAMS, T. A. PORTS, R. A. BAUGHMAN, L. Z. BENET, W. W. PARMLEY, and K. CHATTERJEE Attenuation of Prazosin Effect on Cardiac Output in Chronic Heart Failure Ann Intern Med, September 1, 1979; 91(3): 345 - 349. [Abstract] [PDF]

				J. A. Franciosa, L. A. Nordstrom, and J. N. Cohn Nitrate Therapy for Congestive Heart Failure JAMA, August 4, 1978; 240(5): 443 - 446. [Abstract] [PDF]

				R. N. MacAlpin Vasodilator Therapy for Congestive Heart Failure--New Use for Old Drugs JAMA, August 4, 1978; 240(5): 461 - 462. [Abstract] [PDF]

				J. A. Franciosa Outflow Resistance as a Regulator of Left Ventricular Performance Angiology, May 1, 1978; 29(5): 393 - 401. [PDF]

				L. J. Laslett, A. N. DeMaria, E. A. Amsterdam, and D. T. Mason Hydralazine-Induced Tachycardia and Sodium Retention in Heart Failure: Hemodynamic and Symptomatic Correction by Prazosin Therapy Arch Intern Med, May 1, 1978; 138(5): 819 - 820. [Abstract] [PDF]

				L. Lemberg Digitalis in Congestive Heart Failure: Fact or Fancy Arch Intern Med, March 1, 1978; 138(3): 451 - 452. [Abstract] [PDF]

				Z. Vera Peripheral Circulation in Cardiovascular Disease Arch Intern Med, December 1, 1977; 137(12): 1673 - 1674. [Abstract] [PDF]